PT-141

PT-141 - Bremelanotide MC4R-Selective Melanocortin Research Peptide

PT-141 (bremelanotide) is a 7-amino-acid cyclic peptide derived from Melanotan 2 through metabolic cleavage. It was engineered specifically to isolate the MC4R-mediated central sexual-behavior signaling axis of the broader melanocortin system while removing the MC1R-driven melanogenesis axis. PT-141 is the reference MC4R-selective research melanocortin agonist and was FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women - making it one of the few melanocortin peptides with an approved-drug regulatory record.

Why the MC4R-Selective Profile Matters

The melanocortin receptor family has five subtypes. MC4R is the primary CNS sexual-behavior and appetite-regulation receptor, expressed heavily in the hypothalamus. Melanotan 2 binds all four relevant subtypes (MC1R, MC3R, MC4R, MC5R), producing a broad effect profile that includes skin pigmentation, energy-balance signaling, and MC4R-mediated sexual-behavior signaling. PT-141’s research distinction is that it largely isolates the MC4R signal - the sexual-behavior axis - without the MC1R melanogenesis component. That selectivity is what supports the Vyleesi approved-drug indication.

PT-141 vs Melanotan 2

The two compounds are compared constantly in the melanocortin research literature. PT-141 is literally derived from Melanotan 2, so the comparison is particularly clean.

Forschungsanwendungen

PT-141 is used in studies examining:

• MC4R agonism and central sexual-behavior signaling endpoints
• Hypoactive sexual desire disorder (HSDD) research models
• Erectile function and central arousal pathway research
• Comparative melanocortin-selectivity research (PT-141 vs Melanotan 2 vs Melanotan 1)
• Hypothalamic melanocortin signaling biology
• Non-pigmentation melanocortin-axis research

Technische Daten

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for PT-141 are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical PT-141 literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About PT-141 Research

What is PT-141 used for in research?

It is studied as the reference MC4R-selective melanocortin agonist. Published work covers central sexual-behavior signaling endpoints, hypoactive sexual desire disorder (HSDD) models, erectile-function research, and comparative melanocortin-selectivity research against Melanotan 2 and Melanotan 1.

What is the difference between PT-141 and Melanotan 2?

PT-141 (bremelanotide) was derived from Melanotan 2 by metabolic cleavage. PT-141 is MC4R-selective - it retains the central sexual-behavior axis without the MC1R melanogenesis component. Melanotan 2 binds all melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R), producing a broader effect profile that includes skin pigmentation in addition to libido and appetite endpoints.

Is PT-141 FDA approved?

Yes - PT-141 (bremelanotide) is FDA approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women. Research-grade PT-141 is not sold under the Vyleesi brand and is distinct from the approved drug product. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

Does PT-141 cause skin pigmentation like Melanotan 2?

In published research, PT-141’s MC4R selectivity means it has minimal activity at MC1R (the melanocyte receptor), so the pigmentation axis that is prominent with Melanotan 2 is largely removed. This is the specific research reason PT-141 was developed from Melanotan 2 - to retain the central sexual-behavior signaling while removing the melanogenesis axis.

How is PT-141 stored?

Ungeöffnete Fläschchen werden bei 2–8 °C gelagert und sind mindestens 12 Monate haltbar. Nach der Rekonstitution mit bakteriostatischem Wasser wird die Lösung bei 2–8 °C aufbewahrt und innerhalb von 28–30 Tagen verbraucht.

Reinheitsgarantie

Jede Charge weist eine Reinheit von ≥99 % auf. Senden Sie uns ein Analysezertifikat einer unabhängigen Prüfstelle, und wir stellen Ihnen unabhängig vom Ergebnis eine Gutschrift aus.